Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001683168-25-001712
Filing Date
2025-03-19
Accepted
2025-03-19 13:15:52
Documents
15
Period of Report
2025-03-19
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO 1 xenetic_8ka.htm   iXBRL 8-K/A 28071
5 PRESS RELEASE xenetic_ex9901.htm EX-99.1 15034
6 GRAPHIC image_001.jpg GRAPHIC 6222
  Complete submission text file 0001683168-25-001712.txt   230618

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE xbio-20250319.xsd EX-101.SCH 3020
3 XBRL LABEL FILE xbio-20250319_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE xbio-20250319_pre.xml EX-101.PRE 22362
17 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_8ka_htm.xml XML 3690
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

EIN.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37937 | Film No.: 25751790
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)